BioFocus has achieved a development milestone under its medicinal chemistry services agreement with UCB for the discovery and development of next generation treatments for severe diseases. BioFocus has received an undisclosed milestone payment related to the candidate selection stage.   “This milestone payment from UCB demonstrates BioFocus’ ability to support its client projects through to success,” said Chris Newton, senior vice president, Galapagos Services.  “This innovative collaboration al...